CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination.
COVID-19 vaccine
Disease ontology
Disease similarity
Network module division
Risk factor
Severe adverse reaction
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
23
09
2022
revised:
15
03
2023
accepted:
18
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
ppublish
Résumé
COVID-19 vaccines greatly reduce the risk of infection with SARS-CoV-2. However, some people have adverse reactions after vaccination, and these can sometimes be severe. Gender, age, vaccines, and especially certain diseases histories are related to severe adverse reactions following COVID-19 vaccination. However, there are thousands of diseases and only some are known to be related to these severe adverse reactions. The risk of severe adverse reactions with other diseases remains unknown. Therefore, there is a need for predictive studies to provide improved medical care and minimize risk. Herein, we analyzed the statistical results of existing COVID-19 vaccine adverse reaction data and proposed a COVID-19 vaccine severe adverse reaction risk prediction method, named CVSARRP. The performance of the CVSARRP method was tested using the leave-one-out cross-validation approach. The correlation coefficient between the predicted and real risk is greater than 0.86. The CVSARRP method predicts the risk from adverse reactions to severe adverse reactions after COVID-19 vaccination for 10855 diseases. People with certain diseases, such as central nervous system diseases, heart diseases, urinary system disease, anemia, cancer, and respiratory tract disease, among others, may potentially have increased of severe adverse reactions following vaccination against COVID-19 and experiencing adverse events.
Identifiants
pubmed: 37009244
doi: 10.1016/j.heliyon.2023.e14828
pii: S2405-8440(23)02035-2
pmc: PMC10041818
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e14828Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
There are no conflicts of interests for all authors. We have applied for a patent.
Références
Nat Med. 2021 Aug;27(8):1362-1366
pubmed: 34040262
Korean J Radiol. 2021 Dec;22(12):1938-1945
pubmed: 34719892
JAMA Netw Open. 2021 Dec 1;4(12):e2140364
pubmed: 34935921
Rheumatol Int. 2021 Dec;41(12):2105-2108
pubmed: 34622311
Front Immunol. 2021 Apr 26;12:653786
pubmed: 33981305
J Med Virol. 2021 May;93(5):3133-3142
pubmed: 33595134
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Rheumatol. 2021 Jul;3(7):e469-e470
pubmed: 33817664
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
In Vivo. 2022 Mar-Apr;36(2):1041-1046
pubmed: 35241569
Eur J Heart Fail. 2022 Nov;24(11):2000-2018
pubmed: 36065751
Nucleic Acids Res. 2006 Apr 26;34(7):2137-50
pubmed: 16641319
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Int J Lab Hematol. 2022 Feb;44(1):e10-e12
pubmed: 34258873
Bioinformatics. 2007 May 15;23(10):1274-81
pubmed: 17344234
Aging Med (Milton). 2021 Aug 15;4(3):234-238
pubmed: 34518809